Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Slayback’s Belrapzo Non-Infringement Judgement Is Upheld On Appeal

In Dispute Over Dedication-Disclosure Doctrine

Executive Summary

Slayback Pharma has succeeded in defending itself on appeal that it did not infringe certain patents shielding Eagle Pharmaceuticals’ Belrapzo rapid-infusion bendamustine product, after a district court applied the dedication-disclosure doctrine to bar the originator’s claim.

You may also be interested in...

Teva Fends Off Peers In Bendeka Legal Victory

Teva has fought off US challenges from several of its generics peers over US patents protecting the Bendeka brand that the Israeli firm licenses from Eagle Pharmaceuticals.

Slayback Garners $50m Investment From Everstone

Slayback Pharma and the Everstone Group have struck a deal that will see Everstone invest up to $50m in the US-based complex generics specialist.

Celltrion Selected For Korean-Made Insulin Biosimilar

Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts